pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease. the company’s first commercial products address emphysema, a form of copd (chronic obstructive pulmonary disease) and the largest unmet medical need in pulmonology. with emphysema, breathing becomes increasingly more difficult as the disease progresses. today in the u.s., advanced emphysema patients have no available alternatives but lung volume reduction surgery, which is associated with high morbidity and mortality, and lung transplantation, which is limited by the availability of donor organs. pulmonx has developed the zephyr endobronchial valve (ebv) therapy, a non-surgical, investigational approach to treating emphysema. the minimally invasive zephyr valve is a tiny, one-way valve designed to reduce the volume of the diseased regions of the lung by blocking airflow, in order to improve breathing and increase activity levels. no surgery is involved in the simp
Company profile
Ticker
LUNG
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PULMONX
SEC CIK
Corporate docs
Subsidiaries
Pulmonx Australia Pty Ltd • Pulmonx France SAS • Pulmonx Global B.V. • Pulmonx GmbH • Pulmonx Hong Kong Limited • PulmonX International • Pulmonx Italy Srl • Pulmonx UK Limited • Pulmonx Japan K.K. ...
LUNG stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
8-K
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
2 Apr 24
S-8
Registration of securities for employees
15 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
21 Feb 24
8-K
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
21 Feb 24
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Pulmonx Reports Record Third Quarter 2023 Financial Results
30 Oct 23
Transcripts
LUNG
Earnings call transcript
2023 Q3
30 Oct 23
LUNG
Earnings call transcript
2023 Q2
2 Aug 23
LUNG
Earnings call transcript
2023 Q1
2 May 23
LUNG
Earnings call transcript
2022 Q4
22 Feb 23
LUNG
Earnings call transcript
2022 Q3
6 Nov 22
LUNG
Earnings call transcript
2022 Q2
3 Aug 22
LUNG
Earnings call transcript
2022 Q1
7 May 22
LUNG
Earnings call transcript
2021 Q4
24 Feb 22
LUNG
Earnings call transcript
2021 Q3
3 Nov 21
LUNG
Earnings call transcript
2021 Q2
7 Aug 21
Latest ownership filings
4
Geoffrey Beran Rose
24 Apr 24
144
Notice of proposed sale of securities
22 Apr 24
3
Mehul Joshi
9 Apr 24
4
Geoffrey Beran Rose
26 Mar 24
144
Notice of proposed sale of securities
22 Mar 24
4
Steven S. Williamson
19 Mar 24
3
Steven S. Williamson
19 Mar 24
SC 13G/A
FMR LLC
11 Mar 24
4/A
Geoffrey Beran Rose
7 Mar 24
4/A
John McKune
7 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 95.18 mm | 95.18 mm | 95.18 mm | 95.18 mm | 95.18 mm | 95.18 mm |
Cash burn (monthly) | 2.29 mm | 1.45 mm | 5.06 mm | 5.22 mm | 2.88 mm | 3.25 mm |
Cash used (since last report) | 15.74 mm | 10.00 mm | 34.79 mm | 35.91 mm | 19.78 mm | 22.34 mm |
Cash remaining | 79.44 mm | 85.18 mm | 60.39 mm | 59.28 mm | 75.40 mm | 72.85 mm |
Runway (months of cash) | 34.7 | 58.6 | 11.9 | 11.4 | 26.2 | 22.4 |
Institutional ownership, Q3 2023
91.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 117 |
Opened positions | 11 |
Closed positions | 9 |
Increased positions | 39 |
Reduced positions | 43 |
13F shares | Current |
---|---|
Total value | 327.81 bn |
Total shares | 35.39 mm |
Total puts | 100.00 |
Total calls | 35.20 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Primecap Management | 5.52 mm | $57.05 bn |
BLK Blackrock | 2.94 mm | $30.33 bn |
Point72 Asset Management | 2.93 mm | $30.27 bn |
Flynn James E | 2.47 mm | $23.22 mm |
MS Morgan Stanley | 2.22 mm | $22.93 bn |
FMR | 2.03 mm | $20.97 bn |
Vanguard | 2.02 mm | $20.91 bn |
Deerfield Management | 1.02 mm | $10.52 bn |
KPCB XIII Associates | 994.97 k | $10.28 bn |
Braidwell | 988.56 k | $10.21 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Apr 24 | Geoffrey Beran Rose | Common Stock | Sell | Dispose S | No | Yes | 7.49 | 1,184 | 8.87 k | 306,684 |
22 Mar 24 | Geoffrey Beran Rose | Common Stock | Sell | Dispose S | No | Yes | 9.36 | 1,184 | 11.08 k | 307,868 |
15 Mar 24 | Steven S. Williamson | Common Stock | Grant | Acquire A | No | No | 0 | 205,286 | 0.00 | 205,286 |
15 Mar 24 | Steven S. Williamson | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 8.95 | 425,116 | 3.80 mm | 425,116 |
News
Navigating 6 Analyst Ratings For Pulmonx
3 Apr 24
Piper Sandler Reiterates Overweight on Pulmonx, Maintains $17 Price Target
3 Apr 24
Pulmonx Announces Appointment Of Mehul Joshi As Chief Financial Officer, Effective April 3, 2024
2 Apr 24
Pulmonx Announces Treatment Of The First Patient With The AeriSeal System In CONVERT II Pivotal Trial
26 Feb 24
Analyst Ratings For Pulmonx
23 Feb 24